Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea. People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values. The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m2, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: −2.94 kg and −1.08 kg/m2 at 2 months; −4.23 kg and −1.55 kg/m2 at 4 months, and −5.14 kg and −1.89 kg/m2 at 6 months (all P < 0.001). In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively. After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively. In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively. Among all participants, 27.6% experienced adverse effects, including nausea (20.8%), vomiting (5.2%), diarrhoea (2.5%), and skin rash (3.6%). Documented reasons for discontinuation of treatment were lack of effect (4.4%), adverse events (4.3%), and high cost (3.1%). In real-world settings in Korea, daily treatment with liraglutide…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The majority of RWS conducted in patients initiating incretin-based AOM were retrospective51–71 and included liraglutide users, while only a few studies investigated semaglutide titrated up to 2.4 mg65,66,69–71 (Tables 1 and 2).”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [53]
In the citing paper
“As in RCT, participants were mostly adults (mean age 30.4–55.5 years) and females (60–95%) with class II obesity, except for studies conducted in China and South Korea, enrolling patients with a mean BMI ranging from 30.8 to 33 kg/m2 53,54,62,66.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [53]
In the citing paper
“Similarly, patients with type 2 diabetes were also represented in many studies51,53,54,56,57,59,62,63,65,68–71.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [53]
In the citing paper
“A second RWE study measured gallbladder disorders in patients treated with liraglutide, but recorded 0 events [78].”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [78]
In the citing paper
“Other dermatological AEs reported were rash (3.6%) [78], pruritus (1.7%) [43], urticaria (3%) [73], cellulitis (0-<1%) [67,81,93], and oedema peripheral (6.5%) [67].”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [78]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 45 · Cited by 48
Metadata
- Authors
- Park, J. H., Kim, J. Y., Choi, J. H., Park, H. S., Shin, H.-Y., Lee, J. M., Kim, J.-W., Ko, H.-J., Chon, S., Kim, B. K., Kim, C. S., & Lim, S.
- Affiliations
- Seoul National University Bundang Hospital (KR)
- Konkuk University (KR)
- Asan Medical Center (KR)
- Myongji Hospital (KR)
- Kyungpook National University Hospital (KR)
- Kyung Hee University (KR)
- Kosin University (KR)
- Yonsei University (KR)
- Seoul National University (KR)
- Corresponding author
- Lim, Soo
- ORCID
- Venue
- International Journal of Obesity
- Published
- 2021-01-20
- Volume
- 45
- Issue
- 4
- Pages
- 776-786
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W3121446156
- Cited by
- 48
- References
- 45
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 15 · 2023: 7 · 2022: 5 · 2021: 5
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, obesity treatment, weight loss, GLP-1 receptor agonists, real-world effectiveness, diet and exercise, blood pressure, glycemic control, diabetes mellitus, adverse events, treatment discontinuation, Korean patients
- MeSH terms
- Liraglutide, Heart Disease Risk Factors, Adult, Blood Pressure, Body Weight, Female, Humans, Life Style, Male, Middle Aged, Obesity, Weight Loss, Exercise, Body Mass Index, Republic of Korea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. https://app.cochat.ai/papers/10.1038/s41366-021-00739-z
- The paper
- Park, J. H., Kim, J. Y., Choi, J. H., Park, H. S., Shin, H.-Y., Lee, J. M., Kim, J.-W., Ko, H.-J., Chon, S., Kim, B. K., Kim, C. S., & Lim, S. (2021). Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. International Journal of Obesity. https://doi.org/10.1038/s41366-021-00739-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.